AI Article Synopsis

  • The unfolded protein response (UPR) is linked to various neurodegenerative diseases and is being explored as a potential treatment target.
  • Despite the accumulation of misfolded proteins in conditions like tauopathy, research in specific mouse models shows no activation of the UPR.
  • Findings indicate that the UPR may not play a significant role in the response to tau misfolding and suggests that its relevance in neurodegenerative diseases should be re-evaluated.

Article Abstract

The unfolded protein response (UPR) is commonly associated with a range of neurodegenerative diseases, and targeting UPR components has been suggested as a therapeutic strategy. The UPR surveys protein folding within the endoplasmic reticulum. However, many of the misfolded proteins that accumulate in neurodegeneration are localized so that they do not directly cause endoplasmic reticulum triggers that activate this pathway. Here, using a transgenic mouse model and primary cell cultures along with quantitative PCR, immunoblotting, and immunohistochemistry, we tested whether the UPR is induced in and murine models of tauopathy that are based on expression of mutant tau We found no evidence for the UPR in the rTg4510 mouse model, in which mutant tau is transgenically expressed under the control of tetracycline-controlled transactivator protein. This observation was supported by results from acute experiments in which neuronal cultures expressed mutant tau and accumulated misfolded cytoplasmic tau aggregates but exhibited no UPR activation. These results suggest that the UPR is not induced as a response to tau misfolding and aggregation despite clear evidence for progressive cellular dysfunction and degeneration. We propose that caution is needed when evaluating the implied significance of the UPR as a critical determinant across major neurodegenerative diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597832PMC
http://dx.doi.org/10.1074/jbc.RA119.008263DOI Listing

Publication Analysis

Top Keywords

mutant tau
12
unfolded protein
8
protein response
8
upr
8
neurodegenerative diseases
8
endoplasmic reticulum
8
mouse model
8
upr induced
8
tau
5
pathogenic tau
4

Similar Publications

Background: The retina, an integral part of the central nervous system, can exhibit protein accumulation (Aβ and pTau) associated with neurodegenerative diseases such as Alzheimer’s disease (AD). Biochemical analysis revealed the existence of a distinct primary retinal tauopathy (PReT), differing from AD and primary age‐related tauopathy (PART) brain lysates, suggesting it as a potential precursor for AD tauopathy with possible diagnostic value. However, it remains unclear whether retinal pTau pathology can spread from the eye into the brain.

View Article and Find Full Text PDF

Background: Lamin A is barely expressed in human brain neurons or in murine models such as mice and rats. However, in Alheimer´s disease (AD) brains, neurons in the hippocampus and entorhinal cortex abnormally express lamina A from the initial stages of the disease, being a biomarker together with phosphorylated Tau of the nuclear pathology of AD. Constipation and mesenteric neuronal loss are related to aging and neurodegenerative diseases such as AD.

View Article and Find Full Text PDF

Exposure to environmental chemicals has been associated with Alzheimer’s disease (AD); however, most studies have used a targeted approach to study this relationship. While targeted approaches have been critical to understand mechanisms, they do not reflect real world exposures where an individual is exposed to multiple chemicals at the same time. Exposomics provides the opportunity to use an ‐omics level approach to understand the environmental drivers of disease by measuring the burden of multiple chemicals at the same time.

View Article and Find Full Text PDF

Background: While the formation of β‐amyloid plaques and neurofibrillary “tau” tangles are considered hallmarks of AD pathology, therapeutic targeting of these pathways has been unsuccessful, highlighting the necessity to define the underlying molecular mechanisms driving AD progression. Previous studies from our lab demonstrated that mitochondrial calcium (Ca) overload through neuronal ablation of the mitochondrial Na/Ca exchanger (NCLX) is sufficient to trigger ‘AD‐like’ pathology, including mitochondrial dysfunction, amyloid deposition and tau pathology, and cognitive decline. In addition, we found significant proteomic remodeling of components of the mitochondrial calcium uniporter channel (mtCU), the primary mediator of Ca uptake, in frontal cortex samples isolated post‐mortem from patients diagnosed with non‐familial/sporadic AD.

View Article and Find Full Text PDF

Background: An optimized 6 amino acid peptide (NLSYYT; herein YΦ) derived from the C‐terminus of h19S proteasome activator Rpt5 has been shown to activate the 20S proteasome and promote tau degradation. Further analysis of this peptide has identified the highly conserved leucine in position 5 (P5) as a key part of the 20S activation mechanism to drive degradation of tau monomers in the absence of proteasome activator complexes.

Method: Recombinant peptides were used to identify key amino acids required for binding and activating the h20S proteasome.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!